Contineum Therapeutics, Inc. (CTNM)
NASDAQ · Healthcare
Contineum Therapeutics, Inc. Operating Income 2023–2024
Contineum Therapeutics, Inc. annual/quarterly operating income history and growth rate from 2023 to 2024. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Contineum Therapeutics, Inc. operating income for the quarter ending September 30, 2024 was -13.0 M, a 60.79% increase year-over-year.
- Contineum Therapeutics, Inc. operating income for the twelve months ending September 30, 2024 was 7.0 M.
- Contineum Therapeutics, Inc. annual operating income for 2024 was -50.9 M, a 416.56% decrease from 2023.
- Contineum Therapeutics, Inc. annual operating income for 2023 was 16.1 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Contineum Therapeutics, Inc. Operating Income — FAQ
Contineum Therapeutics, Inc. (CTNM) operating income over the last 2 years — annual and quarterly figures with year-over-year growth and charts.
What is Contineum Therapeutics, Inc.'s operating income?
Contineum Therapeutics, Inc. (CTNM) reported operating income of -$51M for fiscal 2024.
Where can I see CTNM's operating income history?
The chart and table above show Contineum Therapeutics, Inc.'s operating income by year and by quarter, including the growth rate.